On the stock market since 2018, it operates in the world of real estate. It has 5 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
The biggest line carries real weight, but it doesn’t decide everything on its own.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $116.7M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 14 buys and 10 sells. Management buying with its own money is usually read as a good sign.
It pays out $1.56 per share each year — regular cash for whoever holds the stock.
A loss of $39.0M against $116.7M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, CMCTP sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CMCTP is a high-risk stock — not yet profitable, and its future rides on its product catching on.